(A) STC-1 negative in normal tissue; (B) low STC-1 expression in

(A) STC-1 negative in normal tissue; (B) low STC-1 BIBF 1120 mouse expression in tumor tissue; (C) moderate STC-1 expression in tumor tissue; (D) high STC-1 expression in tumor tissue. (E) The average immunostaining scores of STC-1 expression in tumor and normal tissues; (F) Distribution of immunostaining

scores per sample in tumor and adjacent normal tissues. STC-1 mRNA expression profiles in PB and BM from ESCC patients The frequencies of STC-1 mRNA expression detected in PB and BM were 37.6% (32/85) and 21.2% (18/85), respectively, and showed no correlations with each other (P > 0.05), their combination increased the sensitivity to 48.2% (41/85) (Table 2). STC-1 mRNA detected in PB and/or BM was closely associated with its protein high/moderate expression in parallel tumor tissues, regardless of clinical staging (Table 3). Furthermore, in the 40 PB and/or BM samples from patients with benign esophageal disease, only 2 cases (5.0%) Selleckchem BLZ945 were found to be STC-1 mRNA-positive, this frequency was remarkably lower than that in the cancer patients (P < 0.001). Figure 2 shows the typical PCR results. Table 2 STC-1 mRNA expression in peripheral blood and bone marrow of ESCC patients (n = 85) peripheral blood bone

marrow P-value STC-1 (+) STC-1 (−) STC-1 (+) 9 23 0.223 STC-1 (−) 9 44 (+), Chk inhibitor positive; (−), negative. Table 3 Correlation of STC-1 expression in ESCC tissue and peripheral blood/bone marrow (n = 85) Protein expression in ESCC tissue peripheral Edoxaban blood /bone marrow P-value STC-1 mRNA (+) STC-1 mRNA (−) Stage I/II    STC-1 high/moderate 11 11 0.012  STC-1 low/negative 3 18 Stage III/IV    STC-1 high/moderate 24 7 0.008  STC-1 low/negative 3 8 (+), positive; (−), negative. Figure 2 Profiles of STC-1 mRNA expression in the peripheral blood (PB) and bone marrow (BM) of three ESCC patients. Neg, a water blank was used as the negative control; Pos, a resected ESCC tumor tissue was used as the positive control. Association between STC-1 mRNA expression and clinicopathological features As shown in Table 4, STC-1 mRNA expression in PB and BM of ESCC patients

were both associated with lymph metastasis and clinical stage. However, there were no correlations of STC-1 mRNA expression and patients’ gender, age, tumor site, depth and cellular differentiation. Table 4 Association between STC-1 expression and clinicopathological features Characteristics No. peripheral blood bone marrow STC-1 (+) (%) P-value STC-1 (+) (%) P-value Gender     0.674   0.429  Male 54 19(35.2%)   10(18.5%)    Female 31 13(41.9%)   8 (25.8%)   Age     0.242   0.446  <60 35 11 (31.4%)   6(17.1%)    ≥60 50 22 (44.0%)   12(24.0%)   Tumor site     0.632   0.547  Upper thoracic 17 5 (29.4%)   4 (23.5%)    Middle thoracic 33 12 (36.4%)   5 (15.2%)    Lower thoracic 35 15 (42.9%)   9 (25.7%)   Differentiation     0.615   0.575  Well 18 5 (27.8%)   3 (16.7%)    Moderate 38 15(39.5%)   7 (18.4%)    Poor 29 12(41.4%)   8 (27.6%)   T status     0.583   0.329  T1 ~ 2 51 18 (35.3%)   9(17.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>